Clinical Trial Update: Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC [NA]

View source ↗

Summary

A clinical trial update evaluating the safety and efficacy of LVD + C-TACE + Tis/Len for unresectable hepatocellular carcinoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LVD
• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Hong Wu | Conditions: Initially Unresectable Hepatocellular Carcinoma | NA | Status: NOT_YET_RECRUITING